Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05537662 · ClinicalTrials.gov registry record · NA
External Sensing and Neuromodulation to Assess Diabetic Pain Outcomes (XANADO)
A NA study of Chronic Pain, sponsored by Abbott Medical Devices.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05537662: Recruiting NA study of Chronic Pain, sponsored by Abbott Medical Devices.
NCT05537662 is a NA study of Chronic Pain that is actively recruiting participants, run by Abbott Medical Devices. The registered enrollment target is 30 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05537662, a NA study of Chronic Pain, is actively recruiting participants, sponsored by Abbott Medical Devices.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, longitudinal, single-center, non-randomized, open-label, post-market clinical feasibility study to assess the efficacy of neuromodulation therapies (SCS and DRG) for chronic pain patients with diabetes and investigate whether physical and physiological data collected from diabetic and pre-diabetic chronic pain patients is predictive of subjective patient-reported outcomes (PROs) and of adjustments in patient care. These assessments will be made prior to, during, and after the trial of the SCS or DRG system. The study will be carried out in the United States at a single site.
Conditions Studied
Interventions
- DEVICE Standard of care neuromodulation therapy (SCS or DRG)
Study Locations (1)
Illinois
- Rush University Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-06-06 |
| Est. Completion | 2025-04 |
| Phase | NA |
What NCT05537662 shows while recruiting
NCT05537662 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Chronic Pain appearing as the primary indexed condition, and to 1 intervention - of which Standard of care neuromodulation therapy (SCS or DRG) is the first listed.
NCT05537662 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05537662 about?
NCT05537662 is a clinical study titled "External Sensing and Neuromodulation to Assess Diabetic Pain Outcomes (XANADO)". This is a prospective, longitudinal, single-center, non-randomized, open-label, post-market clinical feasibility study to assess the efficacy of neuromodulation therapies (SCS and DRG) for chronic pain patients with diabetes and investigate whether physical and physiological data collected from diab...
What is the current status of trial NCT05537662?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2023-06-06. Estimated completion is 2025-04.
What conditions does trial NCT05537662 study?
This clinical trial studies the following conditions: Chronic Pain.
What interventions are being tested in trial NCT05537662?
The interventions under investigation include: Standard of care neuromodulation therapy (SCS or DRG) (DEVICE).
Who is sponsoring clinical trial NCT05537662?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05537662 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05537662's enrollment target sits among peer trials
30 244th of 301 higher than 48 of 301 other Chronic Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Acceptability, Feasibility and Usability of Various Conversational Data Collection Software
RECRUITING · NA
-
Local Cerebral Oxygenation in Chronic Pain Patients Utilizing Spinal Cord Stimulation
RECRUITING · NA
-
Group Medical Visits and Chiropractic Care for Older Adults With Chronic Spine Pain
RECRUITING · NA
-
Emotional Awareness and Expression Therapy for People With Persistent Pain Following Orthopedic Trauma
RECRUITING · NA
-
Group-based Integrative Pain Management in Primary Care Safety Net Clinics
RECRUITING · NA
-
Opioid and Pain Treatment in Indigenous Communities (OPTIC) Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI